| 前收市價 | 19.27 |
| 開市 | 17.44 |
| 買盤 | 16.15 |
| 賣出價 | 17.00 |
| 拍板 | 125.00 |
| 到期日 | 2024-08-16 |
| 今日波幅 | 15.70 - 17.44 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 無 |
Investor's Business DailyNovo, Lilly Tumble After Study Ties Blindness Disorder To Weight-Loss Drugs
Novo Nordisk stock skidded Wednesday after a new study suggests its diabetes and weight-loss drug can lead to a blindness-causing disease.
BenzingaUsing Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy, Study Finds
A new observational study has identified a potential link between Novo Nordisk A/S’s (NYSE:NVO) GLP-1 drugs, Ozempic and Wegovy (semaglutide), and a serious eye condition known as nonarteritic anterior ischemic optic neuropathy (NAION), which can lead to vision loss. NAION refers to a loss of blood flow to the optic nerve (the cable that connects the eye to the brain). This condition typically causes sudden vision loss in one eye without any pain. Also Read: Joe Biden Suggests Novo Nordisk, Eli
BloombergOzempic Linked to Rare Cases of Vision Loss in Harvard Study
(Bloomberg) -- Novo Nordisk A/S’ best-selling diabetes and weight-loss drugs Ozempic and Wegovy appear to be associated with a higher risk of a rare form of vision loss, according to an analysis by doctors at Massachusetts Eye and Ear, a Harvard-affiliated hospital.Most Read from BloombergUS Allies Say China Is Developing Attack Drones for RussiaChina Can End Russia’s War in Ukraine With One Phone Call, Finland SaysBiden Struggles to Contain Pressure to Abandon Reelection BidHouse Democrats Cons
